Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines

Remibrutinib is currently in clinical development for the treatment of chronic spontaneous urticaria (CSU) in adult patients inadequately controlled by H1-antihistamines. CSU is a distressing skin condition that is characterised by itchy and sometimes painful raised rash or patches for at least six weeks with no known obvious trigger. It may also be accompanied by deep swelling of the face, neck, hands, or feet. CSU can persist for 1–5 years, sometimes longer. CSU can affect daily life in many ways, including sleep deprivation, anxiety, work, school, and social isolation. Antihistamines are the mainstay treatment for chronic spontaneous urticaria. In non-responsive patients, omalizumab is indicated. However, in a significant percentage of patients, it is not possible to achieve complete control of the symptoms.